Skip to main content
. 2012 Oct;11(10):1289–1299. doi: 10.1128/EC.00215-12

Table 4.

MICs of a panel of antifungals in YPD against strains expressing UPC2 mutant alleles

Strain Relevant genotype MIC (μg/ml) after indicated incubation (h)a
FCZ
ICZ
VCZ
TBF
AMB
24 48 24 48 24 48 24 48 24 48
SC5314 UPC2-1/UPC2-2 0.5 4 0.016 0.023 0.008 0.032 0.5 2 0.0313 0.125
UPC2M4A upc2-1Δ::FRT/upc2-2Δ::FRT 0.023 0.032 0.002 0.004 0.002 0.002 <0.016 <0.016 0.0313 0.5
11A8A2A UPC2G648S::FRT/UPC2G648S::FRT 4 >256 0.5 0.75 0.25 >32 2 4 0.016 0.125
SC11A1A UPC2/UPC2G648S::FRT 1 >256 0.032 0.19 0.047 >32 2 4 0.0625 0.25
28A7A10A UPC2A643V::FRT/UPC2A643V::FRT 2 >256 0.125 >32 0.25 >32 1 4 0.016 0.125
SC28A3A UPC2/UPC2A643V::FRT 1 2 0.023 0.047 0.047 >32 1 2 0.0313 0.25
YFA3A2K1 UPC2Y642F::FRT/UPC2Y642F::FRT 2 >256 0.047 0.5 0.064 >32 1 4 0.0625 0.5
SCYFA2A UPC2/UPC2Y642F::FRT 0.75 1 0.023 0.032 0.023 0.19 1 2 0.0313 0.25
AVA1A16A UPC2A646V::FRT/UPC2A646V::FRT 1.5 >256 0.064 0.25 0.064 >32 1 4 0.0313 0.25
SCAVA4 UPC2/UPC2A646V::SAT1-FLIP 0.5 1.5 0.016 0.032 0.016 0.064 1 2 0.0313 0.5
22A1A13A UPC2G304R::FRT/UPC2G304R::FRT 0.19 0.75 0.012 0.023 0.008 0.032 1 2 0.0313 0.5
SC22A3A UPC2/UPC2G304R::FRT 0.75 >256 0.012 0.094 0.023 >32 1 4 0.0313 0.25
25B2D1 UPC2W478C::FRT/UPC2W478C::FRT 1 2 0.047 0.047 0.016 0.5 0.25 1 0.0313 0.25
SC25A1 UPC2/UPC2W478C::FRT 0.5 1 0.016 0.016 0.008 0.032 0.5 1 0.016 0.125
SCUPC2R14A UPC2G648D::FRT/UPC2G648D::FRT 8 >256 >32 >32 0.064 >32 2 4 0.016 0.125
SCUPC2R12A UPC2G648D::FRT/UPC2-2 1.5 >256 0.25 >32 0.047 >32 1 2 0.0313 0.25
SCUPC2R34A UPC2A643T::FRT/UPC2A643T::FRT 1.5 >256 2 >32 0.064 >32 2 2 0.016 0.125
SCUPC2R32A UPC2A643T::FRT/UPC2-2 2 >256 0.016 0.032 0.012 >32 1 2 0.016 0.125
a

Susceptibility was tested at 24 and at 48 h. Azole MICs were determined by Etest method, while terbinafine and amphotericin B MICs were determined by broth microdilution methods. FCZ, fluconazole; ICZ, itraconazole; VCZ, voriconazole; TBF, terbinafine; AMB, amphotericin B.

HHS Vulnerability Disclosure